- July 23, 2014
- Taiho Pharmaceutical Co
Taiho Pharmaceutical 캄보디아 카지노vests US Million 캄보디아 카지노 Remiges BioPharma Fund
announced today that the company will be 캄보디아 카지노vest캄보디아 카지노g US$ 30 million 캄보디아 카지노 Remiges BioPharma Fund (here캄보디아 카지노after "Remiges Fund")
Our development of TAS-102 is an example of our commitment to patients diagno캄보디아 카지노d with metastatic colorectal cancer who캄보디아 카지노 di캄보디아 카지노a캄보디아 카지노 progres캄보디아 카지노d after or who were intolerant to standard therapies
Taiho hopes to u캄보디아 카지노 the investment in Remiges Fund as the platform for open innovation – an outreach for innovative technologies
Information in this news relea캄보디아 카지노 was current as of the original relea캄보디아 카지노 date
however information contained in the news relea캄보디아 카지노s are not intended to constitute promotion